Combined application of PARP7 inhibitor and PD-1 or PD-L1 inhibitor

By combining PARP7 inhibitors and PD-1 or PD-L1 inhibitors, T lymphocyte activity and interferon release are restored, and the problem of poor treatment of certain malignant tumors in the prior art has been solved, and significant tumors have been achieved. Inhibition and extinction effects.

CN119074734APending Publication Date: 2024-12-06CHINA PHARM UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202310661270.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-06
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing PD-1 or PD-L1 inhibitors have limited effectiveness in treating certain malignant tumors such as pancreatic cancer and triple-negative breast cancer. The single-use PARP7 inhibitor is difficult to significantly inhibit the growth of these cancer cells, resulting in poor therapeutic effects. good.

Method used

The combination of PARP7 inhibitors and PD-1 or PD-L1 inhibitors is used to enhance the killing ability of tumor cells by restoring the activity of T lymphocytes and promoting the release of interferons. The specific selection of compounds such as compounds A-2 and Xindi Combination of rimab, dosage and dosage mode optimization.

Benefits of technology

It significantly enhanced the inhibitory effect on tumors, could significantly reduce tumor proliferation and completely resolve tumors in some cases, especially in the CT26 mouse allograft tumor model.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004269108070000021
    Figure BDA0004269108070000021
  • Figure BDA0004269108070000022
    Figure BDA0004269108070000022
  • Figure BDA0004269108070000031
    Figure BDA0004269108070000031
Patent Text Reader

Abstract

The invention discloses a combined application of a PARP7 inhibitor or a pharmaceutically acceptable salt thereof and a PD-1 or PD-L1 inhibitor in preparation of medicines for treating cancers. The combined application has an excellent synergistic anti-tumor effect, and particularly, tumor proliferation can still be obviously inhibited in vivo, and even tumors can be completely eliminated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a combined use of a PARP7 inhibitor and a PD-1 or PD-L1 inhibitor, and in particular to a combined use of the two inhibitors in the preparation of a drug for treating cancer having a synergistic effect. Background Art

[0002] PARP7, a member of the monoPARP protein family, is a new negative regulator of nucleic acid sensors in cells and is overexpressed in tumors. Since cancer cells can inhibit interferon signals through PARP7 and "hide" outside the immune system, many cancer cells rely on PARP7 for survival. Inhibiting PARP7 can restore interferon signaling in cells, restore the body's innate and adaptive immunity, and thus inhibit the growth of cancer cells.

[0003] PD-1 (Programmed Cell Death Protein 1) is a member of the immunoglobulin superfamily and is an immunosuppressive molecule located on the surface of T lymphocytes. It transmits inhibitory signals by binding to the ligand protein PD-L1 produced by tumor cells, inhibiting the proliferation of T lymphocytes and the production of cytokines, thereby leading to the immune escape and growth of tumor cells. Therefore, preventing PD-1 from binding to PD-L1 and restoring the killing ability of suppressed T lymphocytes can effectively inhibit the growth of tumor cells.

[0004] Although PD-1 and PD-L1 inhibitors have made great progress in the treatment of cancer, the response of most patients when used alone is relatively weak and the scope of application is relatively narrow. It is currently believed that patients with high tumor mutation load and high PD-L1 expression are more likely to benefit from it. At the same time, for triple-negative breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, primary peritoneal cancer, prostate cancer, lung cancer, gastric cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, etc., especially pancreatic cancer and triple-negative breast cancer, which have high malignancy and poor prognosis, the single use of PARP7 inhibitors cannot achieve satisfactory therapeutic effects on pancreatic cancer and triple-negative breast cancer.

[0005] US20220265654A1 discloses a PARP7 inhibitor, the combined use of PBN2397 and Pembrolizumab. Although the combination therapy is an effective treatment option, multiple effective treatment options still need to be developed clinically for some malignant tumors. Summary of the invention

[0006] Purpose of the invention: The present invention aims to provide a combined use of a PARP7 inhibitor and a PD-1 or PD-L1 inhibitor with synergistic effects.

[0007] Technical solution: The application of the present invention is the combined use of a PARP7 inhibitor or a pharmaceutically acceptable salt thereof with a PD-1 or PD-L1 inhibitor in the preparation of a drug for treating cancer, wherein the PARP7 inhibitor is preferably selected from any of the following compounds:

[0008]

[0009] Further, more preferably any one of the following compounds:

[0010]

[0011]

[0012] Furthermore, the PD-1 inhibitor is preferably selected from Pembrolizumab, Nivolumab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Zimberelimab, Retifan limab) or Pucotenlimab; more preferably Pembrolizumab, Nivolumab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab or Zimberelimab. The PD-L1 inhibitor is selected from atezolizumab, durvalumab or avelumab.

[0013] The mechanism of the combined application of the present invention is as follows:

[0014] From the anti-tumor mechanism of PARP7 inhibitors and PD-1 or PD-L1 inhibitors, we know that PD-1 or PD-L1 inhibitors can restore the proliferation of T lymphocytes and promote the production of cytokines, thereby improving the effect of killing tumor cells; while PARP7 inhibitors restore the phosphorylation of TBK1 and promote the release of type I interferon, thereby recruiting natural killer cells and cytotoxic T lymphocytes to the tumor site to kill tumor cells. Therefore, the combination of PD-1 or PD-L1 inhibitors and PARP7 inhibitors can reduce the PD-L1-mediated T cell activity inhibition and restore the tumor killing effect of cytotoxic T lymphocytes, thereby exerting a synergistic anti-tumor effect.

[0015] Furthermore, the single dose of the PARP7 inhibitor is preferably 0.05 to 400 mg / kg, more preferably 0.1 to 100 mg / kg, and most preferably 25 mg / kg or 50 mg / kg. The single dose of the PD-1 inhibitor is preferably 0.05 to 40 mg / kg, more preferably 0.1 to 10 mg / kg, and most preferably 0.25 mg / kg or 2.5 mg / kg.

[0016] Furthermore, the combined application is preferably the combination of compound A-2 and PD-1 inhibitor, wherein the PD-1 inhibitor is preferably Sintilimab; the single dose ratio of the two is 10:1 to 100:1, more preferably 10:1 to 20:1, and most preferably 10:1, 20:1 and 100:1; preferably 2 administrations in each administration frequency calculation cycle. More preferably, compound A-2 (25 mg / kg each time, twice a day) is combined with Sintilimab (0.25 mg / kg each time, twice a week), compound A-2 (25 mg / kg each time, twice a day) is combined with Sintilimab (2.5 mg / kg each time, twice a week), and compound A-2 (50 mg / kg each time, twice a day) is combined with Sintilimab (2.5 mg / kg each time, twice a week).

[0017] The combined administration can be oral or injection, specifically intraperitoneal, subcutaneous, intravenous or intramuscular injection.

[0018] Furthermore, the cancer is a mid-to-late stage solid tumor or a blood tumor; specifically preferably, it is triple-negative breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, primary peritoneal cancer, prostate cancer, lung cancer, gastric cancer, liver cancer, kidney cancer, pancreatic cancer, and colorectal cancer; more preferably, it is pancreatic cancer, triple-negative breast cancer, colorectal cancer, and lung cancer; most preferably, it is colorectal cancer, pancreatic cancer, and triple-negative breast cancer.

[0019] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:

[0020] It has excellent synergistic anti-tumor effects, especially it can still significantly inhibit tumor proliferation in vivo and can even completely regress the tumor. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 It is a statistical chart of the combined application of individual tumor volumes in the CT26 mouse homologous transplant tumor model; wherein A is the vehicle control group, B~C are different dose administration groups of sintilimab alone, D and E are different dose administration groups of compound A-2 alone, and F~H are different dose administration groups of compound A-2 combined with sintilimab. DETAILED DESCRIPTION

[0022] The technical solution of the present invention is further described below in conjunction with embodiments.

[0023] Example 1: Study on the anti-tumor effect of combined application in vivo in CT26 mouse homograft tumor model

[0024] 1. Experimental methods

[0025] hPD1-balb / c mice were subcutaneously inoculated with CT26 cells in the right flank to develop tumors. Four days after tumor inoculation, tumors with a size of 50-70 mm were selected. 3 32 mice within the range and based on their tumor volume, were randomly divided into 8 groups, 4 mice in each group. Dosing began on the 2nd day after randomization (the day of randomization was defined as day 0), respectively as follows:

[0026] (1) Vehicle (0.5% sodium carboxymethylcellulose, intragastrically);

[0027] (2) Compound A-2 (25 mg / kg, twice a day, gavage);

[0028] (3) Compound A-2 (50 mg / kg, twice a day, gavage);

[0029] (4) Sintilimab (0.25 mg / kg, twice a week, intraperitoneal injection);

[0030] (5) Sintilimab (2.5 mg / kg, twice a week, intraperitoneal injection);

[0031] (6) Compound A-2 (25 mg / kg, twice a day, gavage) + sintilimab (0.25 mg / kg, twice a week, intraperitoneal injection);

[0032] (7) Compound A-2 (25 mg / kg, twice a day, gavage) + sintilimab (2.5 mg / kg, twice a week, intraperitoneal injection);

[0033] (8) Compound A-2 (50 mg / kg, twice a day, gavage) + sintilimab (2.5 mg / kg, twice a week, intraperitoneal injection).

[0034] The drug was administered continuously for 20 days. The tumor was measured every 2 days during the administration period. The entire study was terminated on the 20th day. The results of the anti-tumor effect are shown in Figure 1 .

[0035] 2. Experimental results

[0036] Depend on Figure 1 It can be seen that the anti-tumor effects of PARP7 inhibitor A-2 and sintilimab alone in the CT26 mouse colon cancer mouse homograft tumor model were weak, while the combination of A-2 and sintilimab could exert excellent anti-tumor effects. The above results show that the combination of PARP7 inhibitors and PD-1 inhibitors has a significant synergistic anti-tumor effect in mice.

Claims

1. A combined use of a PARP7 inhibitor or a pharmaceutically acceptable salt thereof and a PD-1 or PD-L1 inhibitor in the preparation of a drug for treating cancer, characterized in that: The PARP7 inhibitor is selected from any one of the following compounds:

2. The use according to claim 1, characterized in that: The PD-1 inhibitor is selected from pembrolizumab, nivolumab, toripalimab, sintilimab, carrelizumab, tislelizumab, penampalimab, sepalimab, rivalizumab or putalimab.

3. The use according to claim 1, characterized in that: The PD-L1 inhibitor is selected from atezolizumab, durvalumab or avelumab.

4. The use according to claim 1, characterized in that: The PARP7 inhibitor is selected from any one of the following compounds:

5. The use according to claim 2, characterized in that: The PD-1 inhibitor is selected from pembrolizumab, nivolumab, toripalimab, sintilimab, carrelizumab, tilelizumab, penampalimab or sepalimab.

6. The use according to claim 1, characterized in that: The single dose of the PARP7 inhibitor is 0.05 to 400 mg / kg, and the single dose of the PD-1 inhibitor is 0.05 to 40 mg / kg.

7. The use according to claim 4 or 5, characterized in that: The single dose of the PARP7 inhibitor is 0.1 to 100 mg / kg, and the single dose of the PD-1 inhibitor is 0.1 to 10 mg / kg.

8. The use according to claim 1, characterized in that: The cancer is a mid- to late-stage solid tumor or a hematological tumor.

9. The use according to claim 8, characterized in that: The cancer is triple-negative breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, primary peritoneal cancer, prostate cancer, lung cancer, gastric cancer, liver cancer, kidney cancer, pancreatic cancer or colorectal cancer.

10. The use according to claim 9, characterized in that: The cancer is pancreatic cancer, triple-negative breast cancer, colorectal cancer or lung cancer.

Citation Information

Patent Citations

  • Dosage regimens for PARP7 inhibitors

    US20220265654A1